Na Cui
Shanghai University · 227 works · 9,932 citations · h-index 33
Top works
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
- Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study.
- A Review of the Piston Effect in Subway Stations
- Integrated temporary facility location and casualty allocation planning for post-disaster humanitarian medical service
- Design and impact estimation of a reform program of China’s tax and fee policies for low-grade oil and gas resources
- Mining urban recurrent congestion evolution patterns from GPS-equipped vehicle mobility data
- Location planning for transit-based evacuation under the risk of service disruptions
- OA02.01 Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)
- Economic and social effects analysis of mineral development in China and policy implications
- Reliable emergency service facility location under facility disruption, en-route congestion and in-facility queuing
- IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).
- Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer
- Global asymptotic and robust stability of inertial neural networks with proportional delays
- Toxicity profile of labile preservative bronopol in water: The role of more persistent and toxic transformation products
- Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.
- A Best Practice of 5G Layer 2 Network on Intel Architecture
- Characterization and friction-reduction performances of composite coating produced by laser cladding and ion sulfurizing